Voyager Technologies Inc. (NYSE:VOYG) posted its third-quarter fiscal 2026 results after Monday’s closing bell, posting a larger than expected loss per share. Here’s a look at the details.
Voyager Technologies reported quarterly losses of 87 cents per share, which missed the analyst estimate for losses of 85 cents, per Benzinga Pro data.
Quarterly revenue came in at $88.72 million, which beat the Street estimate of $81.38 million and was up from $39.59 million in the same period last year.
Voyager reported the following quarterly highlights:
“Voyager delivered another exceptional quarter, achieving record revenue, record bookings and record backlog, driven by accelerating demand for our technologies and exceptional execution,” said Dylan Taylor, CEO of Voyager Technologies.
“Our record backlog provides meaningful multi-year revenue visibility and raising our full-year guidance reflects this momentum,” Taylor added.
VOYG Stock Price: According to data from Benzinga Pro, Voyager Technologies stock was up 1.75% to $25.02 in Monday’s extended trading.
In a Monday note, Keybanc analyst Michael Leshock maintained an Overweight rating on Voyager Technologies but lowered the price target from $50 to $40, according to Benzinga Pro. This adjustment reflects a cautious outlook despite the company’s recent achievements in space-related projects.
Voyager Technologies has raised its full-year revenue forecast following the successful acquisition of Astrobotic. This acquisition is expected to contribute significantly to Voyager’s revenue in 2026, with an estimated $40 million to $50 million boost.
The company reported record bookings of $113 million and increased its guidance, projecting revenue growth between 66% and 84% for the year. Voyager’s strategic moves are aimed at strengthening its position in the lunar economy.
See More: Top Momentum Stocks
Voyager Technologies has a neutral RSI(14) of 45.04. The stock trades 14.58% below its 50-day SMA of $30.94 and 16.68% below its 200-day SMA of $31.72. The 50-day SMA is below the 200-day SMA, indicating potential resistance levels.
Photo: Anterovium / Shutterstock